Browsing Tag
myeloproliferative neoplasms
3 posts
Is mutant-selective JAK2 inhibition ready for clinical reality after Prelude Therapeutics’ FDA IND clearance?
Prelude Therapeutics gains FDA IND clearance for PRT12396. Read how mutant-selective JAK2 inhibition could reshape MPN drug development.
PharmaEssentia surpasses enrollment goals in clinical trials for hematology candidate BESREMi
PharmaEssentia USA Corporation, a key player in biopharmaceutical innovation and a subsidiary of Taiwan-based PharmaEssentia Corporation, has announced…
Merck to acquire Imago BioSciences to expand blood disorder drugs portfolio
Pharma giant Merck will acquire Imago BioSciences, a Nasdaq-listed clinical stage biopharmaceutical company, for a price of $36…